← GSK overview

GSK vs Replimune: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GSK plc (GSK.LSE)

Q3 2026
▲2▼2

GSK's new drug wins offset pipeline setbacks and legal risks

  • FDA approval of Jiditro and other regulatory wins GSK won FDA approval for Jiditro, its first lung cancer drug, plus regulatory nods for Jemperli and Hibsago. These expand GSK's oncology and specialty portfolios, offering new sales streams.

    New drug approvals are major positive catalysts for future revenue.

  • Strong Q2 results and cost-savings plan GSK reported 5% sales growth in Q2, raised full-year guidance, and announced a £1.9bn cost-savings plan. Specialty Medicines grew 14%, showing core business strength and efficiency gains.

    Financial performance and cost cuts directly boost investor confidence.

  • Pipeline setback and legal threat GSK dropped camlipixant, a potential £2.5bn product, and faces AnaptysBio's lawsuit over Jemperli rights. These create uncertainty about future revenue and legal costs.

    Pipeline failures and litigation are key negative drivers for the stock.

  • Competition and patent cliff concerns Moderna's mRNA flu vaccine challenges GSK's flu franchise, and the dolutegravir HIV patent cliff looms around 2028–29, threatening £2.74bn in H1 2026 sales. Vaccine restructuring cuts 641 Dresden jobs.

    Competitive threats and patent expirations weigh on long-term growth outlook.

September 2026
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

Latest
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

August 2026
▲3▼1

GSK rises on cost cuts, new drug wins, but Moderna threat looms

  • Cost-savings plan and UK investment GSK announced a £1.9bn cost-savings plan to fund late-stage trials, a £400m UK investment, and a new Cambridge R&D hub. This signals efficiency and commitment to innovation, boosting investor confidence.

    This is a major new financial and strategic initiative that drove shares up.

  • Strong Q2 results and raised sales guidance Q2 profit beat expectations, with sales up 5% to over £8.4bn and raised sales guidance. Although EPS guidance was cut on Nuvalent-related interest costs, the overall beat and sales outlook lifted shares.

    Quarterly earnings are a key driver of stock performance and provided positive surprises.

  • Regulatory wins for Jemperli and Hibsago FDA priority review for Jemperli in rectal cancer and world's first approval of Hibsago, a hepatitis B cure, plus Phase III progress for GSK's mRNA flu vaccine, lifted shares on pipeline strength.

    These regulatory milestones represent new growth opportunities and validate GSK's R&D.

  • Moderna's mRNA flu vaccine threat Moderna's FDA-approved mRNA flu vaccine directly threatens GSK's leading flu franchise, potentially pressuring future sales. This competitive threat is a new headwind for GSK.

    It introduces a significant competitive risk that could undermine a key revenue stream.

▲2▼1

GSK pipeline wins and cost cuts drive gains, Moderna flu threat weighs

  • Jemperli priority review for rectal cancer The FDA accepted GSK's Jemperli for priority review in locally advanced rectal cancer, with a decision expected by February 2027. Positive trial data showed patients had no detectable cancer for at least a year. This raises hopes for a new revenue stream and lifts the shares.

    A new regulatory milestone for a key cancer drug adds to GSK's growth outlook.

  • Moderna's mRNA flu vaccine approval Moderna won FDA approval for the first mRNA flu vaccine, for adults 50 and over, directly challenging GSK's flu vaccine business. While uptake depends on pricing and pharmacy stocking, it introduces a new competitor in a market GSK has long led, which could pressure future sales and the share price.

    This is a competitive threat to GSK's established flu vaccine franchise.

  • Hepatitis B cure and mRNA flu advance GSK won the world's first approval for Hibsago, a functional cure for chronic hepatitis B, in Japan. It also advanced its own mRNA flu vaccine to Phase III after positive mid-stage data. Both are new pipeline wins that could drive long-term growth and support the shares.

    Two separate pipeline successes show GSK's research is delivering new products.

▲4

GSK's cost cuts and pipeline push lift shares despite profit dip

  • £1.9bn savings drive and UK investment GSK launched a three-year £1.9bn cost-savings plan to fund late-stage drug trials and simplify the business, plus a £400m UK investment including a new R&D centre. Shares jumped 4.2% as investors welcomed the plan to protect profits while spending on new drugs.

    This is the main new event that directly moved the share price up and shows management's plan to fund growth.

  • Q2 profit beat and raised sales guidance GSK beat second-quarter profit expectations, with sales up 5% to over £8.4bn and core earnings per share up 9%. It raised full-year sales and operating profit guidance to the upper half of its range, though it lowered EPS guidance due to extra interest costs from the Nuvalent deal.

    The earnings beat and guidance raise are new and directly support the share price, while the EPS cut is a real counterweight.

  • AI drug discovery partnership and Cambridge R&D hub GSK expanded its AI drug discovery collaboration with Relation Therapeutics, worth up to $110m, and announced a new Cambridge R&D hub for over 1,000 scientists. These moves aim to speed up finding new drugs and strengthen GSK's long-term pipeline.

    This is a new strategic step that could improve future growth prospects, though the financial impact is longer-term.

  • Record UK lab space demand from GSK prelet GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus helped push UK lab space demand to a record high. This shows GSK is investing in research capacity, but high lab vacancies and slowing construction are a broader industry caution.

    It confirms GSK's commitment to UK R&D and signals demand for its facilities, a new positive signal for the company's growth plans.

July 2026
▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

Q2 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

June 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

Replimune Group Inc (REPL)

Q3 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

July 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

Latest
▲2▼2

FDA approves Replimune's first drug, then company raises $150M

  • FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.

    This is the single biggest new event: approval validates the drug and opens a path to sales.

  • Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.

    It is a new law firm joining the investigation, adding fresh negative pressure.

  • $150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.

    It is a new financing event that directly affects share count and cash position.

  • FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.

    It explains the favorable regulatory environment that helped Replimune's path to approval.

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

  • FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.

    This is the core new event that flipped sentiment and drove the huge price jump.

  • Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.

    Shows the market's immediate, large positive reaction and a key analyst endorsement.

  • Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.

    A real counterweight that could hurt the stock even after the positive panel vote.

© 2026 MarketDXWhy